Empros Pharma AB has secured 80,000,000 SEK in private investments led by Flerie Invest to accelerate the development of its obesity drug EMP16.
Information on the Target
Empros Pharma AB has successfully raised 80,000,000 SEK through private investments to enhance its efforts in developing the obesity drug, EMP16. This investment round was spearheaded by Flerie Invest and is aimed at accelerating EMP16's development, as well as strengthening Empros' team.
EMP16 is an oral, fixed-combination, modified-release formulation that includes orlistat and acarbose, designed for the treatment of obesity. Empros has demonstrated the safety, tolerability, and efficacy of EMP16 in several clinical trials, including a recent proof-of-concept trial published in the journal 'Obesity'. The company anticipates launching EMP16 in the United States by 2027, becoming one of the first post-Mounjaro obesity drugs in the market.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Sweden
The global obesity market is rapidly evolving, with an increasing focus on innovative treatments. In Sweden, the obesity rate is on the rise, prompting the need for effec
Similar Deals
Flerie Invest
invested in
Empros Pharma AB
in 2023
in a Seed Stage deal
Disclosed details
Transaction Size: $7M